{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:33:50Z","timestamp":1789472030278,"version":"build-2803163510"},"reference-count":35,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Child and Adolescent Psychopharmacology"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To evaluate the short-term efficacy and safety of blonanserin in adolescents with schizophrenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This 6-week multicenter, double-blind, randomized, placebo-controlled study investigated fixed-dose blonanserin (8 or 16\u2009mg\/day) in patients 12\u201318 years of age diagnosed with schizophrenia, as indicated by a Positive and Negative Syndrome Scale (PANSS) total score of 60\u2013120 and a Clinical Global Impressions-Severity score of \u22653. The primary endpoint was change from baseline to week 6 in the PANSS total score, using a mixed model for repeated measures analysis. Safety was assessed by the incidence and severity of adverse events (AEs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Among 151 randomized patients, 150 were included in the primary analysis population. Demographic and clinical characteristics were similar across groups at baseline. The rate of study discontinuation was 14.9%, 23.5%, and 28.3% in patients administered with placebo, blonanserin 8\u2009mg\/day, and blonanserin 16\u2009mg\/day, respectively. The least-squares mean change (95% confidence interval [CI]) from baseline to week 6 in PANSS total score was \u221210.6 (\u221216.10 to \u22125.10), \u221215.3 (\u221220.80 to \u22129.86), and \u221220.5 (\u221225.89 to \u221215.16) in patients administered placebo, 8\u2009mg\/day blonanserin, and 16\u2009mg\/day blonanserin, respectively. The 16-mg\/day blonanserin group showed significantly greater reduction in the PANSS total score than the placebo group (least-squares mean difference [95% CI]: \u22129.9 [\u221217.61 to \u22122.25],\n                      <jats:italic toggle=\"yes\">p<\/jats:italic>\n                      \u2009=\u20090.012, effect size: 0.538), although the 8-mg\/day group showed no significant difference. The incidence of AEs such as akathisia, somnolence, and hyperprolactinemia was higher in the blonanserin groups than in the placebo group. AEs associated with blonanserin were generally mild and were consistent with its known profile in adults with schizophrenia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Blonanserin achieved a sufficient efficacy in adolescent patients, and the safety profile was similar to that in adults, which suggests that blonanserin may be a safe treatment option for adolescents with schizophrenia.<\/jats:p>\n                    <jats:p>Study registration number: Japic CTI-111724.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1089\/cap.2021.0013","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T16:34:11Z","timestamp":1644338051000},"page":"12-23","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":17,"title":["Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study"],"prefix":"10.1177","volume":"32","author":[{"given":"Takuya","family":"Saito","sequence":"first","affiliation":[{"name":"Department of Child and Adolescent Psychiatry, Hokkaido University Hospital, Sapporo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Sugimoto","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd., Chuo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reiko","family":"Sakaguchi","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd., Chuo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-9840","authenticated-orcid":false,"given":"Hiroshi","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Sumitomo Dainippon Pharma Co., Ltd., Chuo-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Ishigooka","sequence":"additional","affiliation":[{"name":"Institute of CNS Pharmacology, Shibuya-ku, Tokyo, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743717720197"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.162.3.441"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-019-01425-2"},{"key":"e_1_3_5_5_1","unstructured":"Astra Zeneca: Seroquel\u00ae (quetiapine fumarate) Tablets for the treatment of pediatric patients with schizophrenia (13\u201317 years old) or bipolar mania (10\u201317 years old). Briefing Document for Psychopharmacologic Drugs Advisory Committee Meeting of June 9 and 10 2009."},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-12-150"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S225643"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/npjschz.2014.5"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2011.0092"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.07061035"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200923070-00006"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2016.0189"},{"key":"e_1_3_5_13_1","unstructured":"Guy W: ECDEU Assessment Manual for Psychopharmacology: U.S. Dept. of Health Education and Welfare Public Health Service Alcohol Drug Abuse and Mental Health Administration National Institute of Mental Health Psychopharmacology Research Branch Division of Extramural Research Programs in Rockville MD 1976."},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2008.0144"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12057"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/npr2.12089"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0308-1"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.3109\/15622975.2012.696143"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S59861"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/eip.12412"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/00004850-200301000-00007"},{"key":"e_1_3_5_22_1","first-page":"1073","article-title":"Discontinuation rate and resolution\/remission rate with blonanserin treatment\u2014Post-hoc analysis with long term treatment of blonanserin on schizophrenia [in Japanese]","volume":"14","author":"Ishigooka J","year":"2011","unstructured":"Ishigooka J, , Nakamura H: Discontinuation rate and resolution\/remission rate with blonanserin treatment\u2014Post-hoc analysis with long term treatment of blonanserin on schizophrenia [in Japanese]. Jpn J Clin Psychopharmacol, 14:1073\u20131084, 2011.","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/13.2.261"},{"key":"e_1_3_5_24_1","first-page":"772","article-title":"Effect of discontinuation V","volume":"49","author":"Kishi T","year":"2019","unstructured":"Kishi T, , Ikuta T, , Matsui Y, , Inada K, , Matsuda Y, , Mishima K, , Iwata N: Effect of discontinuation V. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: A meta-analysis. Psychol Med, 49:772\u2013779, 2019.","journal-title":"maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: A meta-analysis. Psychol Med"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/CHI.0b013e3181900404"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2017.16121358"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02354306"},{"key":"e_1_3_5_28_1","unstructured":"Mathis MV: Recommendation of Approvable Action for risperidone (Risperdal) for the Treatment of Schizophrenia and Bipolar I Disorder in Pediatric Patients (response to PWR). Memorandum: Department of Health and Human Services Public Health Service Food and Drug Administration Center for Drug Evaluation and Research Silver Spring MD 2007."},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2013.02.008"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.60.1.82"},{"key":"e_1_3_5_31_1","first-page":"297","article-title":"Clinical evaluation of Blonanserin for schizophrenia\u2014A randomized study comparing Blonanserin with risperidone [in Japanese]","volume":"11","author":"Miura S","year":"2008","unstructured":"Miura S: Clinical evaluation of Blonanserin for schizophrenia\u2014A randomized study comparing Blonanserin with risperidone [in Japanese]. Jpn J Clin Psychopharmacol, 11:297\u2013314, 2008.","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_3_5_32_1","first-page":"2059","article-title":"Clinical evaluation of Blonanserin for schizophrenia\u2014A double-blind trial comparing Blonanserin with haloperidol [in Japanese]","volume":"10","author":"Murasaki M","year":"2007","unstructured":"Murasaki M: Clinical evaluation of Blonanserin for schizophrenia\u2014A double-blind trial comparing Blonanserin with haloperidol [in Japanese]. Jpn J Clin Psychopharmacol, 10:2059\u20132079, 2007.","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.113.127753"},{"key":"e_1_3_5_34_1","volume-title":"Task Force for the Handbook of Psychiatric Measures (eds). Handbook of Psychiatric Measures","author":"Perkins DO","year":"2000","unstructured":"Perkins DO, , Stroup TS, , Lieberman JA: Psychotic disorders measures. In: Rush AJ, Task Force for the Handbook of Psychiatric Measures (eds). Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association, 2000."},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-020-05698-3"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2011.06.021"}],"container-title":["Journal of Child and Adolescent Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/cap.2021.0013","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/cap.2021.0013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:56:16Z","timestamp":1777388176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/cap.2021.0013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["10.1089\/cap.2021.0013"],"URL":"https:\/\/doi.org\/10.1089\/cap.2021.0013","relation":{},"ISSN":["1044-5463","1557-8992"],"issn-type":[{"value":"1044-5463","type":"print"},{"value":"1557-8992","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]}}}